I am hopeful for our chances with the CNPV, despite widespread competition, simply because Alzheimer's Disease is certainly a top -- if the not top -- unaddressed public health priority facing this country. And blarcamesine is the best positioned current AD drug candidate in development with what would be a very popular daily pill, no significant risk approach.
Our best case scenario timing couldn't be better: The one-two punch of an EMA approval recommendation at about the same time as an acceptance into the CNPV program.
Market Data 
Markets 
AI
